Droga Raia - Public Comps and Valuation Multiples

Droga Raia Overview

About Droga Raia

Raia Drogasil SA is a large retail drug store operator in Brazil. The company is engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. Its brands include Impulso, Amplimed, HealthBit, Stix, 4Bio, Drogasil, Raia and others.

Founded

2011

HQ

Employees

53.4K+

Website

rdsaude.com.br

Sectors

Pharmacies

Financials

LTM Revenue $8.0B

LTM EBITDA $642M

EV

$7.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Droga Raia Financials

As of August 2025, Droga Raia reported last 12-month revenue of $8.0B and EBITDA of $642M.

In the same period, Droga Raia generated $2.5B in LTM gross profit and $226M in net income.

See Droga Raia valuation multiples based on analyst estimates

Droga Raia P&L

In the most recent fiscal year, Droga Raia reported revenue of $7.2B and EBITDA of $579M.

Droga Raia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Droga Raia valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$8.0B	XXX	$7.2B	XXX	XXX	XXX
Gross Profit	$2.5B	XXX	$2.1B	XXX	XXX	XXX
Gross Margin	31%	XXX	30%	XXX	XXX	XXX
EBITDA	$642M	XXX	$579M	XXX	XXX	XXX
EBITDA Margin	8%	XXX	8%	XXX	XXX	XXX
EBIT	$421M	XXX	$437M	XXX	XXX	XXX
EBIT Margin	5%	XXX	6%	XXX	XXX	XXX
Net Profit	$226M	XXX	$221M	XXX	XXX	XXX
Net Margin	3%	XXX	3%	XXX	XXX	XXX
Net Debt	XXX	XXX	$510M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Droga Raia including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $8.0B. EBITDA for the last twelve months was $642M. In the most recent fiscal year, Droga Raia achieved $7.2B in revenue and $579M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$8.0B	Analyst estimates available to subscribers	$7.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$2.5B	Analyst estimates available to subscribers	$2.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	31.4% gross margin	Analyst estimates available to subscribers	29.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$642M	Analyst estimates available to subscribers	$579M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	8.0% EBITDA margin	Analyst estimates available to subscribers	8.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$421M	Analyst estimates available to subscribers	$437M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	5.2% EBIT margin	Analyst estimates available to subscribers	6.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$226M	Analyst estimates available to subscribers	$221M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	2.8% net profit margin	Analyst estimates available to subscribers	3.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$510M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Droga Raia

This financial data table provides comprehensive performance metrics for Droga Raia, a company based in Brazil. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Droga Raia generated $8.0B in revenue over the last twelve months.
The company achieved $642M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $2.5B.
Net income over the last twelve months reached $226M.

Fiscal Year Performance

In the most recent fiscal year, Droga Raia reported $7.2B in total revenue.
Fiscal year EBITDA was $579M.
The company maintained a gross profit margin of 29.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 8.1%.
Net profit margin reached 3.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Droga Raia. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Droga Raia Stock Performance

Droga Raia has current market cap of BRL 30.9B (or $5.7B), and EV of BRL 38.8B (or $7.1B).

Market Cap Evolution

Droga Raia Stock Data

As of September 15, 2025, Droga Raia's stock price is BRL 18 (or $3).

See Droga Raia trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$7.1B	$5.7B	XXX	XXX	XXX	XXX	$0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Droga Raia Valuation Multiples

Droga Raia's trades at 1.0x EV/Revenue multiple, and 12.3x EV/EBITDA.

See valuation multiples for Droga Raia and 15K+ public comps

Droga Raia Financial Valuation Multiples

As of September 15, 2025, Droga Raia has market cap of $5.7B and EV of $7.1B.

Equity research analysts estimate Droga Raia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Droga Raia has a P/E ratio of 25.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$5.7B	XXX	$5.7B	XXX	XXX	XXX
EV (current)	$7.1B	XXX	$7.1B	XXX	XXX	XXX
EV/Revenue	0.9x	XXX	1.0x	XXX	XXX	XXX
EV/EBITDA	11.1x	XXX	12.3x	XXX	XXX	XXX
EV/EBIT	17.0x	XXX	16.4x	XXX	XXX	XXX
EV/Gross Profit	2.8x	XXX	n/a	XXX	XXX	XXX
P/E	25.3x	XXX	25.8x	XXX	XXX	XXX
EV/FCF	47.8x	XXX	61.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Droga Raia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Droga Raia Margins & Growth Rates

Droga Raia's last 12 month revenue growth is 12%

Droga Raia's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $32K for the same period.

Droga Raia's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Droga Raia's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Droga Raia and other 15K+ public comps

Droga Raia Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	12%	XXX	14%	XXX	XXX	XXX
EBITDA Margin	8%	XXX	8%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	14%	XXX	XXX	XXX
Rule of 40	20%	XXX	20%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	37%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$32K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	20%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	24%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial